Amitiza is owned by Sucampo Pharma Llc.

Amitiza contains Lubiprostone.

Amitiza has a total of 9 drug patents out of which 4 drug patents have expired.

Expired drug patents of Amitiza are:

• US7064148
• US8097653
• US8389542
• US6982283

Amitiza was authorised for market use on 31 January, 2006.

Amitiza is available in capsule;oral dosage forms.

Amitiza can be used as method for treating constipation in a patient with opioid-induced constipation by opening cic channels; method of treating constipation in a patient with irritable bowel syndrome by opening chloride channels (cic); method for treating constipation by opening cic channels in a mammalian subject, use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient; use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient, method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome; method for the long term treatment of chronic constipation in a human subject, method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient, method for treating opioid-induced constipation, method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome.

The generics of Amitiza are possible to be released after 25 October, 2027.